|Bid||6.14 x 800|
|Ask||6.70 x 1300|
|Day's Range||6.61 - 6.87|
|52 Week Range||2.75 - 8.05|
|Beta (3Y Monthly)||1.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 5, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.13|
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Cerus Corporation (CERS) is presenting its strategic roadmap and outlining its multi-year growth strategy at the 2018 Cerus Institutional Investor Meeting today in Boston. “Our efforts to establish the INTERCEPT Blood System as the standard of care for transfused blood components globally continue to gain traction,” commented William ‘Obi’ Greenman, Cerus’ president and chief executive officer. “Our preliminary Q3 product revenue of $15.4 million underscores the strong market demand for the INTERCEPT Blood System during the quarter, especially in the U.S. Given our preliminary Q3 results, we are raising our full year product revenue guidance from a range of $56 million to $58 million to our new range of $58 million to $60 million, representing an increase of 33% to 38% compared to 2017 product revenue,” continued Greenman.
Cerus Corporation announced today its schedule of key events and presentations at the 2018 AABB Annual Meeting which is taking place in Boston on October 13 through October 16.
Cerus Corporation (CERS) today announced Dr. Laurence Corash, the Company’s co-founder and chief scientific officer has been awarded the prestigious Dale A. Smith Memorial Award by AABB’s National Blood Foundation. The award, which was created in 2002, honors Dale A. Smith, a long-time Baxter Health executive who was responsible for establishing the Fenwal Division. The award is presented to individuals or organizations in recognition of groundbreaking work in utilizing technology for innovation in transfusion medicine or cellular therapies.
Cerus Corporation (NASDAQ:CERS) shareholders, and potential investors, need to understand how much cash the business makes from its core operational activities, as well as how much is invested back into Read More...
Cerus Corporation (CERS) today announced the appointment of Eric Bjerkholt to its Board of Directors. Mr. Bjerkholt currently serves as the chief financial officer of Aimmune Therapeutics, a San Francisco Bay Area biopharmaceutical company focused on the development of treatments to help protect people with food allergies. Mr. Bjerkholt brings over three decades of healthcare and biotech leadership experience to the Cerus Board, which has now been expanded to eight members.
Cerus Corporation today announced that it will host an Institutional Investor Meeting on Tuesday, October 16, 2018 in Boston, Massachusetts.
Cerus Corporation today announced that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, will present and provide a corporate update at the Cantor Fitzgerald 2018 Global Healthcare Conference in New York City on Tuesday, October 2, 2018 at 3:25 p.m.
Cerus Corporation today announced the appointment of Timothy L. Moore to its Board of Directors. Mr. Moore, who currently serves as executive vice president, technical operations for Kite, a Gilead Company, brings over three decades of experience in engineering, manufacturing, and technical operations in the biopharmaceutical industry.
Cerus Corporation (NASDAQ:CERS), a US$1.04b small-cap, operates in the healthcare industry, which faces more complex and interdependent challenges, requiring multi-pronged, collaborative, and technology-enabled business models. Healthcare analysts are forecasting forRead More...
NEW YORK, Aug. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Evertec, ...
Cerus (CERS) delivered earnings and revenue surprises of 9.09% and 11.11%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Concord, California-based company said it had a loss of 10 cents per share. The biomedical products company posted revenue of $15.4 million in the period. Cerus expects full-year revenue in the range ...
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Cerus Corporation (NASDAQ: CERS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:15 PM Eastern Time. ...
This morning, WallStEquities.com observes BioDelivery Sciences International Inc. (NASDAQ: BDSI), Biohaven Pharmaceutical Holding Co. Ltd (NYSE: BHVN), Biogen Inc. (NASDAQ: BIIB), and Cerus Corp. (NASDAQ: CERS). The Biotechnology industry consists of companies that are engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development.
Cerus Corporation announced today that its second quarter results will be released on Thursday, August 2, 2018, after the close of the stock market. The company will host a conference call and webcast at 4:15 P.M.
Cerus Corporation announced today that the U.S. Department of the Navy will implement pathogen-reduction for all apheresis platelets collected at Navy Blood Donor Centers.
Losses were broad based as eight out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: BioDelivery Sciences International Inc. (NASDAQ: BDSI), Biogen Inc. (NASDAQ: BIIB), Biohaven Pharmaceutical Holding Co. Ltd (NYSE: BHVN), and Cerus Corp. (NASDAQ: CERS).
NEW YORK, NY / ACCESSWIRE / June 25, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Cerus Corporation (CERS), a biomedical products company focused in the field of blood transfusion safety. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites that may be present in donated blood.